Myosin-binding protein C slows cardiac myofibril relaxation kinetics. [PDF]
Dvornikov AV, Harris SP.
europepmc +1 more source
Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. [PDF]
Bilen O +19 more
europepmc +1 more source
Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction. [PDF]
Kakturskiy L +6 more
europepmc +1 more source
Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. [PDF]
Reza N +12 more
europepmc +1 more source
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy [PDF]
Canter, Charles, et al,
core +1 more source
Myosin Mayhem: Losing (or Gaining) Its Chill in Hypertrophic Cardiomyopathy. [PDF]
Colson BA.
europepmc +1 more source
Exploration of the Role of Cilostazol in Brugada Syndrome: Mechanisms, Therapeutic Potential, and Implications in the Prevention of Ventricular Arrhythmias. [PDF]
Iqbal M, Putra ICS, Karwiky G, Achmad C.
europepmc +1 more source
PTUPB, a soluble epoxide hydrolase/cyclooxygenase‑2 dual inhibitor, reduces endothelial‑to‑mesenchymal transition and improves doxorubicin‑induced vascular and cardiac toxicity. [PDF]
Dhulkifle H +6 more
europepmc +1 more source
Unexplained Syncope in Athletes: Unmasking Left Ventricular Outflow Tract Obstruction. [PDF]
Bavishi A +9 more
europepmc +1 more source
Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy. [PDF]
Caro-Codón J +9 more
europepmc +1 more source

